Camille R. Mazurek

MatchAlign: Parsing GFA and GAF Alignment Files

Camille R. Mazurek

Provides tools for extracting segment paths from Graphical Fragment Assembly ('GFA') and Graph Alignment Format ('GAF') files.parse_paths_gfa() reads P (path) and W (walk) records and returns a named list of segment identifiers for each accession.parse_paths_gaf() parses the path string from each alignment …

SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity

Ninaad Lasrado, Marjorie Rowe, Katherine McMahan, Nicole P. Hachmann et autres

Current COVID-19 vaccines provide robust protection against severe disease but minimal protection against acquisition of infection. Intramuscularly administered COVID-19 vaccines induce robust serum neutralizing antibodies (NAbs), but their ability to boost mucosal immune responses remains to be determined. In this study, we …

us (code pays fourni par la source)

B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S

Catherine Jacob-Dolan, Michelle A. Lifton, Olivia Powers, Jessica Miller et autres

The viral vector-based COVID-19 vaccine Ad26.COV2.S has been recommended by the WHO since 2021 and has been administered to over 200 million people. Prior studies have shown that Ad26.COV2.S induces durable neutralizing antibodies (NAbs) that increase in coverage of variants over time, …

us, nl (code pays fourni par la source)

Waning immunity and IgG4 responses following bivalent mRNA boosting

Ninaad Lasrado, Ai‐ris Y. Collier, Jessica Miller, Nicole P. Hachmann et autres

Messenger RNA (mRNA) vaccines were highly effective against the ancestral SARS-CoV-2 strain, but the efficacy of bivalent mRNA boosters against XBB variants was substantially lower. Here, we show limited durability of neutralizing antibody (NAb) responses against XBB variants and isotype switching to …

us (code pays fourni par la source)

Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques

Katherine McMahan, Frank Wegmann, Malika Aïd, Michaela Sciacca et autres

Abstract A limitation of current SARS-CoV-2 vaccines is that they provide minimal protection against infection with current Omicron subvariants 1,2 , although they still provide protection against severe disease. Enhanced mucosal immunity may be required to block infection and onward transmission. Intranasal …

us, nl (code pays fourni par la source)

Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86

Ninaad Lasrado, Ai‐ris Y. Collier, Nicole P. Hachmann, Jessica Miller et autres

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant BA.2.86 has over 30 mutations in spike compared with BA.2 and XBB.1.5, which raised the possibility that BA.2.86 might evade neutralizing antibodies (NAbs) induced by vaccination or infection. In this study, we show …

us (code pays fourni par la source)

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.2.86

Ninaad Lasrado, Ai‐ris Y. Collier, Nicole P. Hachmann, Jessica Miller et autres

ABSTRACT The continued evolution of SARS-CoV-2 may lead to evasion of vaccine immunity and natural immunity. A highly mutated Omicron variant BA.2.86 has recently been identified with over 30 amino acid changes in Spike compared with BA.2 and XBB.1.5. As of September …

us (code pays fourni par la source)

SARS-CoV-2 RBD dimers elicit response comparable to VLPs in mice

J. Christopher Love, Sergio A. Rodriguez‐Aponte, Lisa H. Tostanoski, Neil C. Dalvie et autres

We report the direct comparison of monomeric, dimeric and trimeric RBD protein subunit vaccines to a virus-like particle (VLP) displaying RBD. After two and three doses, a RBD dimer and trimer elicited antibody levels in mice comparable to an RBD-VLP. Furthermore, an …

il, ru, us (code pays fourni par la source)

Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques

Jingyou Yu, Paul V. Thomas, Michaela Sciacca, Cindy Wu et autres

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines demonstrate reduced protection against acquisition of BA.5 subvariant but are still effective against severe disease. However, immune correlates of protection against BA.5 remain unknown. We report the immunogenicity and protective efficacy of vaccine regimens …

us (code pays fourni par la source)

Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters

Ninaad Lasrado, Ai‐ris Y. Collier, Jessica Miller, Nicole P. Hachmann et autres

The SARS-CoV-2 Omicron variant has continued to evolve. XBB is a recombinant between two BA.2 sublineages, XBB.1 includes the G252V mutation, and XBB.1.5 includes the G252V and F486P mutations. XBB.1.5 has rapidly increased in frequency and has become the dominant virus in …

us (code pays fourni par la source)

Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1

Jessica Miller, Nicole P. Hachmann, Ai‐ris Y. Collier, Ninaad Lasrado et autres

To study the neutralization escape of SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1 and the effectiveness of mRNA mono and bi-valent boosters.

us (code pays fourni par la source)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters

Ai‐ris Y. Collier, Jessica Miller, Nicole P. Hachmann, Katherine McMahan et autres

Immunogenicity of BA.5 Bivalent mRNA Vaccine BoostersTo the Editor: Waning immunity after messenger RNA (mRNA) vaccination and the emergence of variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to reduced mRNA vaccine efficacy against symptomatic infection and severe disease.1,2 …

us (code pays fourni par la source)